Evaluation of methylated DCR1 as a biomarker for response to adjuvant irinotecan-based therapy in stage III colon cancer: cancer and leukaemia Group B 89803 (Alliance)

MLA

Lynn Symonds, et al. “Evaluation of Methylated DCR1 as a Biomarker for Response to Adjuvant Irinotecan-Based Therapy in Stage III Colon Cancer: Cancer and Leukaemia Group B 89803 (Alliance).” Epigenetics, vol. 17, Apr. 2022, pp. 1715–25. EBSCOhost, https://doi.org/10.1080/15592294.2022.2058225.

APA

Lynn Symonds, Ming Yu, YuHong Zhang, Fang-Shu Ou, Tyler J. Zemla, Kelly Carter, Monica Bertagnolli, Federico Innocenti, Linda JW Bosch, Gerrit A Meijer, Beatriz Carvalho, William M. Grady, & Stacey A. Cohen. (2022). Evaluation of methylated DCR1 as a biomarker for response to adjuvant irinotecan-based therapy in stage III colon cancer: cancer and leukaemia Group B 89803 (Alliance). Epigenetics, 17, 1715–1725. https://doi.org/10.1080/15592294.2022.2058225

Chicago

Lynn Symonds, Ming Yu, YuHong Zhang, Fang-Shu Ou, Tyler J. Zemla, Kelly Carter, Monica Bertagnolli, et al. 2022. “Evaluation of Methylated DCR1 as a Biomarker for Response to Adjuvant Irinotecan-Based Therapy in Stage III Colon Cancer: Cancer and Leukaemia Group B 89803 (Alliance).” Epigenetics 17 (April): 1715–25. doi:10.1080/15592294.2022.2058225.